GlassScriptPhysician profile
Ronald A Hirsch
NPI 1821072125
$11,851.37
in general payments reported to CMS, 2019-2025
41 companies · $2,113 in 2025
The $2,113 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $1,117 · 2021: $1,650 · 2022: $1,884 · 2023: $1,680 · 2024: $2,116 · 2025: $2,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,908.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,193.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,877.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,130.89 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $1,018.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $865.55 | 2019-2025 | |
| Abbvie INC. | $733.19 | 2021-2025 | |
| Amgen INC. | $443.77 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.65 | 2019-2025 | Jardiance, Stiolto Respimat |
| Abbott Laboratories | $330.49 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mylan Specialty L.P. | $312.90 | 2020-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.57 | 2025 | Caplyta |
| Amarin Pharma, INC. | $238.42 | 2019-2022 | |
| Astellas Pharma US INC | $229.80 | 2022-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.56 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $216.04 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $149.47 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $113.40 | 2024 | |
| Exact Sciences Corporation | $104.35 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $95.82 | 2024-2025 | Auvelity |
| Allergan, INC. | $91.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.78 | 2022 | |
| Dexcom, INC. | $71.40 | 2023-2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $68.90 | 2022-2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $63.58 | 2020-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $61.48 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.52 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $49.12 | 2022 | |
| Lundbeck LLC | $48.74 | 2024-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $34.83 | 2021 | |
| Alkermes, INC. | $32.40 | 2023-2025 | Aristada, Lybalvi |
| Ultragenyx Pharmaceutical INC. | $31.06 | 2020-2021 | |
| Abiomed | $23.49 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.58 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $19.92 | 2020 | |
| Pulmonx Corporation | $19.11 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $18.76 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2024 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $14.12 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.71 | 2022 | |
| Horizon Therapeutics Plc | $11.62 | 2019 | |
| Kaleo, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.